Fatih Kus

15PUBLICATIONS
106CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersMolecular targetsTraditional Chinese medicine and treatmentsTeacher education and professional development of educators
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (15)

|Jun 26, 2026
Dose-Adjusted EPOCH-R in Aggressive B-Cell Lymphomas: Efficacy, Molecular Prognostic Factors, and Real-World Outcomes from a Multicenter Turkish Cohort-A Turkish Oncology Group (TOG) Study.

|Nov 27, 2025
KELIM PSA as a Prognostic Biomarker in Castration-Resistant Prostate Cancer Treated with ARPI.

Fatih Atalah, Fatih Kuş, Aydın Acarbay

|Nov 17, 2025
Real-world comparison of doxorubicin-ifosfamide versus gemcitabine-docetaxel regimens in metastatic uterine leiomyosarcoma: a multicenter retrospective study.

Salih Tunbekici, Gokhan Sahin, Haydar Cagatay Yuksel

|Sep 11, 2025
Palbociclib in liposarcoma: real-world multicenter data from the Turkish Oncology Group (TOG).

Fatih Kus, Hasan Cagri Yildirim, Dogan Bayram

|Aug 28, 2025
Malignancies After Renal Transplantation: Frequency, Etiology, and Prognosis-A Single Center Experience.

Fatih Atalah, Aydın Acarbay, Akgün Karakök

|Jul 10, 2025
Prognostic and predictive significance of the pan-immune-inflammation value in endometrial cancer patients undergoing adjuvant therapy.

Elvin Chalabıyev, Rashad Ismayılov, Fatih Kus

Pageof 3

Frequent Collaborators

6 joint publications

Hasan Çağrı Yıldırım

3 joint publications

Zafer Arık

2 joint publications

Fatih Atalah

2 joint publications

Ertugrul Bayram